Home >> Signaling Pathways >> Apoptosis >> PD-1/PD-L1 interaction

PD-1/PD-L1 interaction

Programmed death-1 (PD-1) is a receptor on T cells that has been shown to suppress activating signals from the T cell receptor when bound by either of its ligands, Programmed death-ligand 1 (PD-L1) or PD-L2. When PD-1 expressing T cells contact cells expressing its ligands, functional activities in response to antigenic stimuli, including proliferation, cytokine secretion, and cytotoxicity are reduced. PD-1/PD-Ligand interactions down regulate immune responses during resolution of an infection or tumor, or during the development of self tolerance.

Interference with the PD-1/PD-L1 interaction has also shown enhanced T cell activity in chronic infection systems. Chronic lymphocytic chorio meningitis virus infection of mice also exhibits improved virus clearance and restored immunity with blockade of PD-L1.

In addition to enhancing immunologic responses to chronic antigens, blockade of the PD-1/PD-L1 pathway has also been shown to enhance responses to vaccination, including therapeutic vaccination in the context of chronic infection.

Products for  PD-1/PD-L1 interaction

  1. Cat.No. Product Name Information
  2. GC50482 (D)-PPA 1 PD-1/PD-L1 interaction inhibitor (D)-PPA 1  Chemical Structure
  3. GC32704 Atezolizumab (MPDL3280A)

    A humanized monoclonal antibody IgG1, resistant to PD-L1

    Atezolizumab (MPDL3280A)  Chemical Structure
  4. GC31719 Avelumab (Anti-Human PD-L1, Human Antibody) Avelumab (Anti-Human PD-L1, Human Antibody)  Chemical Structure
  5. GC38740 BMS-1001 hydrochloride BMS-1001 hydrochloride  Chemical Structure
  6. GC31753 BMS-1166 (PD-1/PD-L1-IN1) BMS-1166 (PD-1/PD-L1-IN1)  Chemical Structure
  7. GC38131 BMS-1166 hydrochloride BMS-1166 hydrochloride  Chemical Structure
  8. GC62682 BMSpep-57 hydrochloride BMSpep-57 hydrochloride  Chemical Structure
  9. GC62253 Camrelizumab Camrelizumab  Chemical Structure
  10. GC35913 Durvalumab A humanized anti-PD-L1 monoclonal antibody Durvalumab  Chemical Structure
  11. GC38044 Fraxinellone Fraxinellone  Chemical Structure
  12. GC34218 Nivolumab (BMS-936558) Nivolumab is a programmed death-1 (PD-1) blocking antibody used to treat advanced (metastatic) non-small cell lung cancer. Nivolumab (BMS-936558)  Chemical Structure
  13. GC36767 NP-12 NP-12  Chemical Structure
  14. GC36768 NP-12 (TFA) NP-12 (TFA)  Chemical Structure
  15. GC19225 PD-1-IN-1 PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4. PD-1-IN-1  Chemical Structure
  16. GC34928 PD-1-IN-17 PD-1-IN-17  Chemical Structure
  17. GC34929 PD-1-IN-17 TFA PD-1-IN-17 TFA  Chemical Structure
  18. GC63517 PD-1-IN-24 PD-1-IN-24  Chemical Structure
  19. GC15142 PD-1/PD-L1 inhibitor 1 PD-1/PD-L1 interaction inhibitor PD-1/PD-L1 inhibitor 1  Chemical Structure
  20. GC16762 PD-1/PD-L1 inhibitor 2 PD-1/PD-L1 inhibitor 2  Chemical Structure
  21. GC16258 PD-1/PD-L1 Inhibitor 3

    PD-1/PD-L1 interaction inhibitor

    PD-1/PD-L1 Inhibitor 3  Chemical Structure
  22. GC62658 PD-1/PD-L1-IN 7 PD-1/PD-L1-IN 7  Chemical Structure
  23. GC62125 PD-1/PD-L1-IN-10 PD-1/PD-L1-IN-10  Chemical Structure
  24. GC62688 PD-1/PD-L1-IN-8 PD-1/PD-L1-IN-8  Chemical Structure
  25. GC62387 PD-1/PD-L1-IN-9 PD-1/PD-L1-IN-9  Chemical Structure
  26. GC62502 PD-1/PD-L1-IN-NP19 PD-1/PD-L1-IN-NP19  Chemical Structure
  27. GC63984 PD-L1-IN-1 PD-L1-IN-1  Chemical Structure
  28. GC31878 PD1-IN-2 PD1-IN-2  Chemical Structure
  29. GC19531 Pembrolizumab

    A IgG4-kappa monoclonal antibody against PD-1

    Pembrolizumab  Chemical Structure
  30. GC10469 Sulfamethoxypyridazine long-acting sulfonamide antibiotic Sulfamethoxypyridazine  Chemical Structure
  31. GC19131 Tomivosertib eFT508 is a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib  Chemical Structure
  32. GC61946 TPP-1 TPP-1  Chemical Structure

31 Item(s)

per page

Set Descending Direction